Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Annexin Pharmaceuticals AB (publ) is a biotechnology company headquartered in Stockholm, Sweden, established in 2014. The company focuses on developing ANXV, a drug candidate based on recombinant Annexin A5 protein, designed to treat a variety of cardiovascular and inflammatory diseases by protecting and repairing blood vessels and modulating immune responses. ANXV acts by binding phosphatidylserine, a lipid exposed on stressed or damaged cells, which helps control inflammation and tissue injury. Annexin Pharmaceuticals holds a strong patent portfolio covering the drug’s production process and therapeutic uses, aiming to address significant unmet medical needs in indications such as retinal vein occlusion and cancer. With a research-driven approach, the company is conducting clinical trials to evaluate ANXV’s efficacy and safety, positioning itself as a leader in the Annexin A5 biological area within the pharmaceutical and biotech sector.
kr 1.07
kr 0.01 (-0.46%)
EOD Jun 23, 2026 · Twelve Data
Negative free cash flow of -kr 37M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 39M
▲ +26.6% YoY
Op. Margin
—
ROIC
-148.47%
▲ +96.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 39M
▲ +26.2% YoY
Op. Cash Flow (TTM)
-kr 37M
▲ +25.1% YoY
Net Debt
-kr 27M
Net Cash Position
Cash & Equiv.
kr 27M
Continue Research
Annexin Pharmaceuticals AB (publ) (ANNX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Annexin Pharmaceuticals AB (publ) scores 20/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Annexin Pharmaceuticals AB (publ) scores 20 out of 100 on Intrinsiqq's quality score, passing 2 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -148.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ANNX.XSTO's valuation and scores 20/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.